Simultaneous detection of circulating immunological parameters and tumor biomarkers in early stage breast cancer patients during adjuvant chemotherapy
- 14 January 2016
- journal article
- research article
- Published by Springer Nature in Cellular Oncology
- Vol. 39 (3) , 211-228
Abstract
Background Chemotherapy-induced immune suppression has mainly been studied in patients with advanced cancer, but the influence of chemotherapy on the immune system in early stage cancer patients has so far not been studied systematically. The aim of the present study was to monitor the immune system during anthracycline- and taxane-based adjuvant chemotherapy in early stage breast cancer patients, to assess the impact of circulating tumor cells on selected immune parameters and to reveal putative angiogenic effects of circulating endothelial cells. Methods Peripheral blood samples from 20 early stage breast cancer patients were analyzed using a flow cytometric multi-color of antibodies to enumerate lymphocyte and dendritic cell subsets, as well as endothelial and tumor cells. An enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of various serological factors. Results During chemotherapy, all immunological parameters and angiogenesis surrogate biomarkers showed significant decreases. The numbers of circulating tumor cells showed significant inverse correlations with the numbers of T helper cells, a lymphocyte subset directly related to effective anti-tumor responses. Reduced T helper cell numbers may contribute to systemic immunosuppression and, as such, the activation of dormant tumor cells. Conclusions From our results we conclude that adjuvant chemotherapy suppresses immune function in early stage breast cancer patients. In addition, we conclude that the presence of circulating tumor cells, defined as pan-cytokeratin+, CD326+, CD45− cells, may serve as an important indicator of a patient’s immune status. Further investigations are needed to firmly define circulating tumor cells as a predictor for the success of breast cancer adjuvant chemotherapy.Keywords
Funding Information
- Fondazione IRCCS Policlinico San Matteo, Pavia (Hospital Research) (08067611)
This publication has 87 references indexed in Scilit:
- CD4 lymphopenia to identify end-of-life metastatic cancer patientsEuropean Journal of Cancer, 2013
- Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapyBMC Cancer, 2012
- Circulating tumour cells in non-metastatic breast cancer: a prospective studyThe Lancet Oncology, 2012
- Effects of SDF-1–CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cellsExperimental Cell Research, 2011
- Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian CancerCancer Research, 2011
- Camouflage and sabotage: tumor escape from the immune systemCancer Immunology, Immunotherapy, 2011
- Circulating endothelial cells as biomarkers in clinical oncologyMicrovascular Research, 2010
- Chemokines and chemokine receptors: new insights into cancer-related inflammationTrends in Molecular Medicine, 2010
- Significant Impairment in Immune Recovery After Cancer TreatmentNursing Research, 2009
- Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing AgentsCancer Cell, 2008